XCancer

PReCedeNT Trial: Phase III Randomised Controlled Open Label Trial of Lutetium 177 PRRT Plus Chemotherapy Versus PRRT Aalone in FDG Avid Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Description:

Given the absence of a prospective study to establish this treatment regimen, we designed a Phase 3 Randomized Controlled Trial to evaluate the combination of PRRT and CAPE-TEM-based chemotherapy in patients with FDG-positive metastatic well-differentiated NETs.

Sponsor:

Tata Memorial Hospital

Phase:

Phase 3

Contacts:

Sushil K Yadav, MSc

sushilyadav.crc@gmail.com

912224177000 ext 7019

Government Study Link:

NCT07185672 - Click here to see study on

ClinicalTrials.gov

Lutetium 177 PRRT

Isotope(s):
Target(s):
  • SSTR+
Chelator: DOTA